
News|Videos|October 25, 2017
Healthcare Team: Initial Conversations
Advertisement
Episodes in this series

Advertisement
Related to this article

U.S. counties where more residents had medical debt in collections had higher rates of late-stage lung, head and neck, colorectal and several other cancers, according to a study of 2,958 counties published in October 2026 in JAMA Network Open.

Libtayo survival data, a rare positive osteosarcoma trial and new ADCs for breast, lung and stomach cancers are among ESMO 2026 abstracts to watch.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

From a personalized melanoma vaccine to new options for biliary, stomach, lung and endometrial cancers, here are 5 ESMO 2026 abstracts to watch.

Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.

The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.

A study of 52,236 patients with cancer found that episodes of unintended weight loss affected 46.63% of patients and were tied to shorter overall survival.
Advertisement
Advertisement
Trending on CURE
1
Diagnosed With Stage 4 Breast Cancer Weeks After Giving Birth
2
Libtayo, Osteosarcoma and More: 5 Other ESMO 2026 Abstracts to Watch
3
Stage 4 Breast Cancer: How a Second Opinion Saved Her Life
4
What Is a Personalized Cancer Vaccine? What Patients Should Know
5















